1. Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
2. Funding the Working Capital Requirement of our Company
3. To meet out the General Corporate Purposes
C-11, Block- C Community Centre Janakpuri A-3
New Delhi
Delhi
110058
011-45699388
info@avienbio.com
www.avienbio.com
Skyline Financial Services Pvt Ltd
Pursuant to the Regulation 30 of the SEBI Listing Regulations, Prostarm Info Systems has informed that the Management of the Company will be participating in InsightX 2026 - Choice Virtual Investor Conference on Friday, June 12, 2026 at 1 PM to 2 PM. Discussion will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and relevant notifications and amendments made thereto from time to time, PNGS Gargi Fashion Jewellery has informed that the Company’s management will be meeting Investors/Analysts in InsightX 2026 - Choice Virtual Conference on Thursday - June 11, 2026 at 12:00 pm- 1:00 pm. No unpublished price sensitive information will be shared during the aforesaid meeting.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 29 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bright Outdoor Media has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, June 12, 2026, to consider and approve the following matters: 1. Migration of the listing and trading of the equity shares of the Company from the SME Platform of BSE to the Main Board of BSE and listing of the equity shares on the Main Board of the National Stock Exchange of India, subject to the receipt of requisite approvals and compliance with applicable regulatory requirements; 2. Approval of the Postal Ballot Notice seeking the approval of the members for the aforesaid migration of the listing and trading of the equity shares of the Company from the SME Platform of BSE to the Main Board of BSE and listing on the Main Board of the National Stock Exchange of India; 3. Any other matter(s) with the permission of the Chair.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The issue size of Avience Biomedicals Ltd. IPO is ₹0.00 - 0.00 crore.
The Avience Biomedicals Ltd. IPO opens for subscription on and closes on .
The price range of Avience Biomedicals Ltd. IPO is ₹0.00 to ₹0.00.
The lot size of Avience Biomedicals Ltd. IPO is shares.
The registrar of Avience Biomedicals Ltd. IPO is Skyline Financial Services Pvt Ltd .
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.